Trials / NCT04355689
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
Completed Phase 1 / Phase 2 Drug / neuroprotection
- Sponsor
- Nacuity Pharmaceuticals, Inc.
- Treatment
- NPI-001; Placebo
- Gene
- Not gene-specific
- Conditions
- Usher Syndromes
- Ages
- 18 Years to no upper limit
- Enrollment
- 49 participants
- Started
- 2020-09-03
- Main results expected
- 2025-06-20
- Results posted
- Not yet
- Record last updated
- 2026-07-01
What the study is testing
This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
Where it runs
Australia (4)
- Queensland Eye Institute, Brisbane
- CERA, Melbourne
- Lions Eye Institute, Perth
- Sydney Eye Hospital / Save Sight Institute, Sydney